Automate remote ischemic conditioning Device
The device provides a non-invasive, safe and accurate device to automate remote ischemic conditioning (RIC). Placed around the arm, the device for the first time allows simple, consistent, reliable and cost-effective automation of Remote Ischemic Conditioning (RIC) at the point of care. RIC activates innate mechanisms of metabolic protection and has the potential to revolutionize the treatment of ischemic related reperfusion injury. RIC can be activated in a non-invasive manner, safely applying sequences of short, controlled periods of reduced or no blood flow (ischemia) in a limb followed by resumed blood flow (reperfusion). The device is highly portable and time efficient, delivering four cycles of simple-to-administer treatment in less than 40 minutes. The device is compatible with current standard-of-care treatments.
该仪器使用了非侵入性、安全、准确的技术,实现远隔缺血处理(RIC)的自动化。在手臂附近放置,该仪器第一次实现了在护理点进行简易、一致、可靠、性价比高的远隔缺血处理(RIC)的自动化。RIC可激活代谢保护的先天机制, 并有望变革与缺血有关的再灌注损伤治疗。RIC可以非侵入性的方式被激活,安全实施序列的步骤,在较短的控制时间内肢体减少或没有血液流动，之后恢复血液流动（再灌注）。该仪器高度便携和具有时效性，在40分钟内提供四个周期的易操作治疗, 与现有的标准护理治疗兼容。Clinical Applications: RIC has been shown to reduce the larger damage from ischemic reperfusion injury to cardiac and other organs, including myocardial infarctions (heart attack), cardiac surgery, stroke, trauma, and organ transplantation.
临床应用: RIC已被证实可以降低缺血再灌注损伤，心脏和其他器官，包括心肌梗塞（心脏病发作），心脏手术，中风，外伤，和器官移植的损伤
Stage: The device has obtained CE Mark certification in Europe and Health Canada approval. The device is manufactured in China and is seeking joint venture, distribution and investment opportunities.
阶段: 该仪器已获得欧盟CE认证和加拿大的健康认证，在中国制造，并正在寻求合资，分销及投资机会
技术售让
生物技术/制药/医疗
医疗器械/医疗设备
